Literature DB >> 33183562

Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.

Tanvir Abbass1, Ross D Dolan2, Nicholas MacLeod2, Paul G Horgan2, Barry J Laird3, Donald C McMillan2.   

Abstract

BACKGROUND: Assessment of malnutrition, performance status and systemic inflammation are routine aspects of clinical assessment in patients with advanced cancer. There is increasing evidence that body composition measurements from routine staging CT also have prognostic value. To date the relative prognostic value of Malnutrition Universal Screening Tool (MUST), Eastern Cooperative Oncology Group Performance Status (ECOG-PS), modified Glasgow Prognostic score (mGPS) and CT derived body composition analysis in patients with advanced lung cancer has not been examined. The aim of the present study was to examine this relationship.
METHODS: Clinicopathological characteristics including MUST, ECOG-PS, mGPS and body composition data were collected pre-radiotherapy from a prospectively maintained database of patients with advanced lung cancer (n = 643). Using the MUST score, patients were classified into low (MUST = 0, n = 189), medium (MUST = 1, n = 341) and high (MUST ≥ 2, n = 113) malnutrition risk and their relationship to systemic inflammatory response (SIR) and body composition with clinical outcomes were examined using univariate and multivariate analyses. Primary outcome of the study was overall survival.
RESULTS: Compared with the patients at low nutrition risk (MUST = 0), patients at moderate to high risk (MUST 1-≥2) had poorer ECOG-PS > 1 (p < 0.01), elevated modified frailty index (mFI) (p < 0.001), elevated mGPS (p < 0.001), lower skeletal muscle index (SMI, p < 0.01) but not lower skeletal muscle density (SMD, p = 0.115). MUST was an important prognostic marker of 12 months overall survival (p = 0.001). On multivariate analysis, higher MUST (HR 1.16, 95% CI 1.03-1.31, p < 0.05), ECOG-PS > 1 (HR 1.23, 95% CI 1.10-1.39, p < 0.001), elevated mGPS (HR 1.20, 95% CI 1.09-1.33, p < 0.001) were independently associated with overall survival.
CONCLUSION: A large proportion of patients (71%) with advanced lung cancer were at moderate to high nutrition risk. Higher malnutrition risk and elevated inflammatory status were independently associated with poor overall survival. MUST, ECOG-PS and mGPS all had independent prognostic value and may form an important prognostic framework in treatment decision making and resource utilization.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Body composition; Lung cancer; Malnutrition universal screening tool (MUST); Modified glasgow prognostic score (mGPS); Performance status (ECOG-PS); Skeletal muscle density (SMD); Skeletal muscle index (SMI)

Year:  2020        PMID: 33183562     DOI: 10.1016/j.clnesp.2020.08.003

Source DB:  PubMed          Journal:  Clin Nutr ESPEN        ISSN: 2405-4577


  4 in total

Review 1.  Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis.

Authors:  Shaofang Feng; Huiwen Mu; Rong Hou; Yunxin Liu; Jianjun Zou; Zheng Zhao; Yubing Zhu
Journal:  Int J Clin Oncol       Date:  2022-05-23       Impact factor: 3.402

2.  Prognostic value of computed tomography derived skeletal muscle mass index in lung cancer: A meta-analysis.

Authors:  Xue-Lin Pan; Hong-Jun Li; Zhen Li; Zhen-Lin Li
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

Review 3.  Cancer cachexia: a nutritional or a systemic inflammatory syndrome?

Authors:  Josh McGovern; Ross D Dolan; Richard J Skipworth; Barry J Laird; Donald C McMillan
Journal:  Br J Cancer       Date:  2022-05-06       Impact factor: 9.075

4.  The Association between Muscle Quantity and Overall Survival Depends on Muscle Radiodensity: A Cohort Study in Non-Small-Cell Lung Cancer Patients.

Authors:  Wouter A C van Amsterdam; Netanja I Harlianto; Joost J C Verhoeff; Pim Moeskops; Pim A de Jong; Tim Leiner
Journal:  J Pers Med       Date:  2022-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.